問卷

TPIDB > Search Result

Search Result

篩選

List

175Cases

2026-03-16 - 2034-01-30

Phase III

Not yet recruiting
Efficacy, safety, and pharmacokinetics of once-weekly subcutaneous cagrilintide 2.4 mg as monotherapy and in combination with subcutaneous semaglutide 2.4 mg (CagriSema) for weight management in overweight or obese children and adolescents.
  • Condition/Disease

    Obesity

  • Test Drug

    Cagrilintide CagriSema Semaglutide

Participate Sites
4Sites

Recruiting4Sites

2019-11-01 - 2029-03-31

Phase I

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
3Sites

Recruiting3Sites

2020-01-09 - 2026-02-28

Phase III

Completed
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
6Sites

Recruiting6Sites

2020-02-05 - 2021-12-30

Phase II

Completed
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
9Sites

Recruiting9Sites

2020-06-01 - 2029-05-31

Phase III

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
7Sites

Recruiting7Sites

2020-09-01 - 2027-05-01

Phase I

Completed
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
4Sites

Recruiting4Sites

2020-09-15 - 2025-10-08

Phase II

Completed
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
7Sites

Recruiting6Sites

2020-09-20 - 2027-12-31

Phase II

Completed
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
5Sites

Not yet recruiting1Sites

Recruiting4Sites

2021-04-20 - 2024-07-02

Phase III

Completed
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
7Sites

Recruiting7Sites

2021-05-18 - 2023-12-31

Phase II

Completed
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
10Sites

Recruiting5Sites

Terminated5Sites